IN2013CN00342A - - Google Patents

Info

Publication number
IN2013CN00342A
IN2013CN00342A IN342CHN2013A IN2013CN00342A IN 2013CN00342 A IN2013CN00342 A IN 2013CN00342A IN 342CHN2013 A IN342CHN2013 A IN 342CHN2013A IN 2013CN00342 A IN2013CN00342 A IN 2013CN00342A
Authority
IN
India
Prior art keywords
carrier
agent
renal fibrosis
treating renal
producing
Prior art date
Application number
Other languages
English (en)
Inventor
Yoshiro Niitsu
Keiko Kajiwara
Yasunobu Tanaka
Miyono Miyazaki
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Publication of IN2013CN00342A publication Critical patent/IN2013CN00342A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6919—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a ribbon or a tubule cochleate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IN342CHN2013 2010-06-17 2011-06-17 IN2013CN00342A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010138070 2010-06-17
PCT/JP2011/063910 WO2011158933A1 (ja) 2010-06-17 2011-06-17 腎線維症処置剤

Publications (1)

Publication Number Publication Date
IN2013CN00342A true IN2013CN00342A (ru) 2015-07-03

Family

ID=45348325

Family Applications (1)

Application Number Title Priority Date Filing Date
IN342CHN2013 IN2013CN00342A (ru) 2010-06-17 2011-06-17

Country Status (12)

Country Link
US (2) US20130136789A1 (ru)
EP (1) EP2583691B1 (ru)
JP (2) JP2012020995A (ru)
KR (1) KR101967868B1 (ru)
CN (1) CN102933233A (ru)
AU (1) AU2011266057B2 (ru)
CA (1) CA2802414C (ru)
ES (1) ES2712086T3 (ru)
IN (1) IN2013CN00342A (ru)
RU (2) RU2635460C2 (ru)
TW (1) TWI549691B (ru)
WO (1) WO2011158933A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009221164A (ja) 2008-03-17 2009-10-01 Nitto Denko Corp 肺線維症処置剤
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
JP5950428B2 (ja) 2010-08-05 2016-07-13 日東電工株式会社 線維化組織から正常組織を再生するための組成物
JP6340162B2 (ja) 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
US9585857B2 (en) 2013-01-18 2017-03-07 Cornell University Methods of treating diseases associated with high-fat diet and vitamin A deficiency using retinoic acid receptor agonists
JP6602034B2 (ja) 2014-04-02 2019-11-06 日東電工株式会社 標的化分子およびその使用
KR102256453B1 (ko) 2014-04-07 2021-05-25 닛토덴코 가부시키가이샤 소수성 약물 전달용 신규한 폴리머계 하이드로트로프
CN105597085A (zh) * 2015-12-17 2016-05-25 哈尔滨博翱生物医药技术开发有限公司 成纤维细胞生长因子-21在治疗肾纤维化中的应用
JP6833456B2 (ja) * 2016-11-02 2021-02-24 日東電工株式会社 皮膚線維症処置剤
KR102352489B1 (ko) 2019-12-09 2022-01-18 전남대학교산학협력단 소수성 개질된 글리콜 키토산 나노입자 및 이를 이용한 신장 표적화 약물 전달체

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238924A (en) 1984-05-03 1993-08-24 Merck & Co., Inc. Treatment of renal diseases with ace inhibitors
JP3810020B2 (ja) 1993-04-22 2006-08-16 武田薬品工業株式会社 腎疾患の予防または治療剤
US6183774B1 (en) * 1996-01-31 2001-02-06 Collaborative Laboratories, Inc. Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts
US6334999B1 (en) * 1999-08-27 2002-01-01 Research Development Foundation Liposomal aerosols for delivery of chemotherapeutic retinoids to the lungs
PT1132086E (pt) 2000-01-31 2006-09-29 Pfizer Prod Inc Utilizacao de agonistas selectivos para o receptor da prostaglandina (pge2) 4 (ep4) para o tratamento de falha renal aguda e cronica
BR0006556A (pt) * 2000-12-28 2002-09-17 Apsen Farmaceutica S A Composição farmacêutica para uso tópico à base de corticosteróide para tratamento de fimose
IL143366A0 (en) 2001-05-24 2002-04-21 Harasit Medical Res Services & Treatment of renal fibrosis
JP2004043459A (ja) 2002-05-24 2004-02-12 Sumitomo Pharmaceut Co Ltd ＴＧＦ−β阻害活性を有する低分子化合物からなる医薬
EP1454625A1 (en) 2003-03-06 2004-09-08 Speedel Development AG Pyridylsulfonamidyl-pyrimidines for the treatment of diabetic nephropathies
EP1746885A4 (en) 2004-05-03 2010-09-08 Univ Virginia ADENOSINE A2A RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETIC NEPHROPATHY
KR100613342B1 (ko) 2004-12-16 2006-08-21 동부일렉트로닉스 주식회사 반도체 소자 및 그 제조방법
ES2900801T3 (es) * 2004-12-22 2022-03-18 Nitto Denko Corp Portador de fármacos y kit de portador de fármacos para inhibir la fibrosis
JP2009221164A (ja) * 2008-03-17 2009-10-01 Nitto Denko Corp 肺線維症処置剤
JP2007099641A (ja) 2005-09-30 2007-04-19 Tsumura & Co インドールキノキサリン類化合物、その製造方法およびそれを用いた医薬組成物
JP5342834B2 (ja) 2008-09-05 2013-11-13 日東電工株式会社 骨髄線維症処置剤
JP2009292725A (ja) 2006-09-01 2009-12-17 Stelic Institute Of Regenerative Medicine 腎疾患改善剤
TWI407971B (zh) * 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
JP2009007258A (ja) 2007-06-26 2009-01-15 Kowa Pharmaceutical Co Ltd Ｐａｉ−１産生抑制作用を有する３−アニリノ−２−シクロアルケノン誘導体
JP2009029750A (ja) 2007-07-27 2009-02-12 Kowa Co アリールプロパン誘導体を有効成分とする糖化最終産物形成阻害剤
CA2698812A1 (en) * 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
JP2009178143A (ja) 2008-02-01 2009-08-13 Stelic Institute Of Regenerative Medicine 脂肪性肝炎−肝癌モデル動物
KR20110051214A (ko) * 2008-07-30 2011-05-17 닛토덴코 가부시키가이샤 약물 담체
TWI556831B (zh) * 2008-09-12 2016-11-11 日東電工股份有限公司 纖維化疾病之造影劑
JP2010077101A (ja) 2008-09-29 2010-04-08 Toray Ind Inc 腎線維症の治療剤又は予防剤
EP3012324A3 (en) * 2009-12-09 2016-07-06 Nitto Denko Corporation Modulation of hsp47 expression
RU2632888C2 (ru) * 2011-06-08 2017-10-11 Нитто Денко Корпорейшн СОЕДИНЕНИЯ ДЛЯ НАЦЕЛЕННОЙ ДОСТАВКИ ЛЕКАРСТВЕННОГО СРЕДСТВА И УСИЛЕНИЯ АКТИВНОСТИ siPHK

Also Published As

Publication number Publication date
TWI549691B (zh) 2016-09-21
CN102933233A (zh) 2013-02-13
EP2583691A1 (en) 2013-04-24
RU2017136720A3 (ru) 2019-02-08
RU2017136720A (ru) 2019-02-08
CA2802414C (en) 2018-01-09
CA2802414A1 (en) 2011-12-22
WO2011158933A1 (ja) 2011-12-22
AU2011266057A1 (en) 2013-01-10
RU2711531C2 (ru) 2020-01-17
ES2712086T3 (es) 2019-05-09
EP2583691A4 (en) 2016-04-27
US20150259683A1 (en) 2015-09-17
JP5873589B2 (ja) 2016-03-01
TW201204389A (en) 2012-02-01
KR20130121813A (ko) 2013-11-06
EP2583691B1 (en) 2019-01-16
KR101967868B1 (ko) 2019-08-19
AU2011266057B2 (en) 2014-12-04
RU2013101969A (ru) 2014-07-27
JP2012020995A (ja) 2012-02-02
RU2635460C2 (ru) 2017-11-13
US20130136789A1 (en) 2013-05-30
JP2015155459A (ja) 2015-08-27

Similar Documents

Publication Publication Date Title
IN2013CN00342A (ru)
MX354137B (es) Composiciones topicas de minociclina y metodos de uso de la misma.
SG10201810110RA (en) Extreme pcr
NZ717728A (en) Stable formulations of a hyaluronan-degrading enzyme
GB2510091A (en) Collaborative processor and system performance and power management
MX348537B (es) Diferencia de celulas madre pluripotentes.
GEP201706733B (en) Anti-il-23 antibodies
EP2751632A4 (en) SYSTEM AND METHOD FOR IMPOSING THE CONSUMER POWER OF A DATA CENTER OF SPECIFIC LEVELS BY DYNAMICALLY ADJUSTING THE EQUIPMENT UTILIZATION RATE
PT2710123T (pt) Linha celular de linfócitos compreendendo células t gama-delta, método de composição e produção resultante dos mesmos
EP2639293A4 (en) CELL CULTURE CHAMBER, METHOD FOR PRODUCING THE SAME, FABRIC MODEL USING THE CELL CULTURE CHAMBER AND METHOD FOR PRODUCING THE SAME
EP2755291B8 (en) Vehicle charging system, vehicle charging method, power supply system, and power supply method
AU342950S (en) Utility pump
GB2500128A (en) Colonoscopy-preparation
PH12014502870A1 (en) Method of producing recombinant iduronate-2-sulfatase
MX2016000557A (es) Conversion basada en moleculas pequeñas de celulas somaticas en celulas de cresta neural.
MX344896B (es) Método de operación de la fermentación de un substrato gaseoso que contiene monóxido de carbono.
MX354183B (es) Metodo de operacion de la fermentacion de un substrato gaseoso que comprende hidrogeno.
PH12014501240A1 (en) Film containing compositions
EP2752933A4 (en) BATTERY ELECTROLYTE AND METHOD FOR THE PRODUCTION THEREOF, AND BATTERY WITH THE ELECTROLYTE
IN2014DN10038A (ru)
MY164728A (en) Treatment of bone marrow edema (oedema) with polysulfated polysaccharides
EP2733204A4 (en) METHOD FOR THE PRODUCTION OF A PLURIPOTENTIAL CELL WITH FERMENTABLE BACTERIUM
IN2014DN08664A (ru)
GB201111216D0 (en) Composition and method
EP2554658A4 (en) METHOD FOR CELL CULTURE IN A SYSTEM COMPRISING LAMININ-5